Cpfen400 mg

Pain Relief

Cpfen is established for the relief of mild to moderate pain, including headache, dental pain, muscular pain, backache, and minor injury-related pain.

Fever Reduction

Cpfen is established for the reduction of fever in adults and in children aged 6 months and older.

Primary Dysmenorrhea (Menstrual Pain)

Cpfen is established for the treatment of primary dysmenorrhea.

Rheumatoid Arthritis and Osteoarthritis

Cpfen is guideline-supported for relief of the signs and symptoms of rheumatoid arthritis and osteoarthritis at prescription-level doses, used under the supervision of a healthcare professional rather than as routine self-medication. It is a symptomatic anti-inflammatory and analgesic treatment and does not modify the underlying course of these diseases; in rheumatoid arthritis it is typically used as an adjunct alongside disease-modifying therapy rather than as monotherapy.

Migraine

Cpfen has an adjunct, self-care role for acute migraine attacks in adults (single 400 mg dose, as needed); it is not a first-line preventive therapy for migraine.

Fever and Pain in Children

Cpfen is guideline-supported (per current AAP-aligned pediatric guidance) for fever and pain relief in infants and children 6 months of age and older; use in infants under 6 months should only be under a doctor's direction. See Pediatric Uses and Dosage for details.

Ibuprofen is well absorbed after oral administration, with peak plasma concentrations typically reached within 1 to 2 hours of dosing. It is extensively metabolized in the liver and eliminated with a serum half-life of approximately 1.8 to 2.0 hours. Ibuprofen and its metabolites are excreted primarily in the urine, with essentially complete elimination occurring within 24 hours of the last dose. Because elimination is largely renal, drug and metabolite clearance can be reduced in patients with significant renal impairment.

• Take Cpfen with food, milk, or a full glass of water to reduce the chance of stomach upset.
• Swallow tablets and capsules whole with water; do not crush the sustained-release capsule.
• Shake the oral suspension well before each use and measure the dose with an accurate oral measuring device, not a household spoon.
• Avoid lying down for about 10 minutes after taking a dose of Cpfen.
• Do not take more Cpfen than directed, and do not combine it with other products that also contain Cpfen or another NSAID unless advised by a healthcare professional.
• If a dose is missed, take it as soon as remembered unless it is almost time for the next dose; do not double the dose.

• Low-dose aspirin (cardioprotective use): Cpfen can competitively block aspirin's binding site on platelet cyclooxygenase, reducing aspirin's antiplatelet effect; if both are used, Cpfen should be taken at least 8 hours before or at least 30 minutes after an immediate-release low-dose (81 mg) aspirin dose.
• Anticoagulants (e.g., warfarin): combined use increases the risk of gastrointestinal bleeding through additive effects on platelet function and the gastric mucosa.
• ACE inhibitors and angiotensin receptor blockers: Cpfen can reduce their antihypertensive effect by inhibiting prostaglandins involved in blood pressure regulation, and combined use can increase the risk of kidney impairment.
• Diuretics: Cpfen can blunt the natriuretic and antihypertensive effect of diuretics, and the combination (especially with an ACE inhibitor) raises the risk of reduced kidney function.
• Lithium: Cpfen can reduce renal clearance of lithium, raising plasma lithium levels and the risk of toxicity.
• Methotrexate: Cpfen can reduce renal clearance of methotrexate, increasing the risk of methotrexate toxicity.
• Other NSAIDs or aspirin used regularly together: combining Cpfen with another NSAID or regular aspirin increases the risk of gastrointestinal ulceration and bleeding without added benefit.
• SSRIs (selective serotonin reuptake inhibitors): combined use with Cpfen increases the risk of gastrointestinal bleeding through additive effects on platelet function and the stomach lining.

Common Side Effects

• Stomach upset, heartburn, or nausea
• Headache or dizziness
• Drowsiness or fatigue
• Mild fluid retention or swelling
• Skin rash

Serious Side Effects (Seek Medical Attention)

• Signs of stomach bleeding: black or bloody stools, vomiting blood or material that looks like coffee grounds, or severe stomach pain that does not go away (see Precautions and Warnings for gastrointestinal risk details)
• Signs of a heart attack or stroke: chest pain, shortness of breath, sudden weakness on one side of the body, or slurred speech (see Precautions and Warnings for cardiovascular risk details)
• Signs of kidney problems: decreased urination, swelling in the ankles/feet, or unusual tiredness (see Precautions and Warnings for renal risk details)
• Signs of a severe allergic reaction: hives, facial or throat swelling, difficulty breathing, or wheezing
• Severe skin reaction: blistering, peeling skin, or a widespread rash
• Yellowing of the skin or eyes, or dark urine, which may indicate liver involvement

Pregnancy

Cpfen should not be used in pregnancy unless clearly necessary, and only on medical advice. In the first and second trimester (up to about 20 weeks), Cpfen should be avoided unless a doctor determines it is clearly needed, and if used, the lowest effective dose for the shortest possible time should be chosen. From about 20 weeks of pregnancy onward, health authorities advise avoiding Cpfen and other NSAIDs because they can cause rare but serious kidney problems in the unborn baby, leading to low amniotic fluid (oligohydramnios); this effect has been seen with as little as 48 hours of use. If a doctor decides Cpfen is necessary between about 20 and 30 weeks, it should be used at the lowest effective dose for the shortest duration, with ultrasound monitoring of amniotic fluid if use continues beyond 48 hours. From about 30 weeks of pregnancy (third trimester) onward, Cpfen should not be used at all, because of the added risk of premature narrowing or closure of the fetal ductus arteriosus (see Contraindications). This guidance reflects an FDA safety communication that is more specific than older, general "avoid in late pregnancy" label language, and pregnant patients should discuss any pain or fever relief needs with their healthcare provider rather than self-medicating with Cpfen.

Breastfeeding

Cpfen is generally considered a preferred pain reliever and anti-inflammatory choice during breastfeeding by independent lactation references, because it passes into breast milk in very small amounts (well under 1% of the maternal dose relative to the infant's weight) and has a short half-life. No adverse effects have been documented in breastfed infants in published reports of maternal Cpfen use. As with any medicine during breastfeeding, Cpfen should be used at the lowest effective dose for the shortest duration needed, and a healthcare provider should be consulted for individual guidance, especially for premature or unwell infants.

• Gastrointestinal bleeding risk: Cpfen and other NSAIDs can cause stomach or intestinal bleeding, ulceration, or perforation at any time during use, with or without warning symptoms; the risk is higher in people over 60, those with a prior ulcer or GI bleed, those taking corticosteroids, anticoagulants, or other NSAIDs/aspirin, those who drink 3 or more alcoholic drinks per day, and with higher doses or longer duration of use.
• Cardiovascular thrombotic risk: NSAIDs including Cpfen can increase the risk of serious cardiovascular thrombotic events, including heart attack and stroke, which can occur early in treatment and may increase with longer use or higher doses; Cpfen should be avoided immediately before or after coronary artery bypass graft (CABG) surgery.
• Kidney (renal) caution: Cpfen can reduce blood flow to the kidneys and, with long-term use, has been associated with kidney papillary necrosis and other renal injury; the risk is higher in patients who are dehydrated, elderly, have pre-existing kidney disease, heart failure, or liver dysfunction, or who take diuretics or ACE inhibitors/ARBs together with Cpfen.
• Interaction with low-dose aspirin: Cpfen may reduce the heart-protective antiplatelet effect of low-dose aspirin if taken too close together; see Interactions for recommended timing.
• Asthma and aspirin/NSAID sensitivity: in patients with a history of asthma, nasal polyps, or a prior reaction to aspirin or another NSAID, Cpfen can trigger severe bronchospasm or a severe allergic-type reaction; such patients should not use Cpfen (see Contraindications).
• Fluid retention, hypertension, and heart failure: Cpfen can cause fluid retention and edema and may worsen high blood pressure or existing heart failure; blood pressure should be monitored, particularly at the start of treatment.
• Hepatic caution: Cpfen can, rarely, cause abnormal liver test results or liver injury; it should be used with caution in patients with hepatic impairment, and liver function should be monitored during prolonged use.
• Long-term use and eye monitoring: patients on long-term Cpfen therapy may benefit from periodic eye examinations, as visual disturbances have been reported with extended NSAID use.
• Systemic lupus erythematosus and mixed connective tissue disease: patients with these conditions may have an increased risk of aseptic meningitis with NSAID use, including Cpfen; any new severe headache, fever, or neck stiffness during treatment should be reported to a doctor promptly.

The most common effects of Cpfen overdose are nausea, vomiting, stomach pain, drowsiness, dizziness, and headache; ringing in the ears (tinnitus) can also occur with large doses. Less commonly, a large overdose can cause gastrointestinal bleeding, a drop in blood pressure, difficulty breathing, kidney problems, or, rarely, seizures, particularly in young children or with very large ingestions. Do not induce vomiting unless specifically directed to do so by a doctor or poison control service. If an overdose of Cpfen is suspected, contact a poison control center or seek emergency medical care immediately; treatment is generally supportive, and a doctor may recommend measures such as activated charcoal if the ingestion is recent.

• Children: Cpfen is not recommended in infants under 6 months of age except on a doctor's specific advice. For children 6 months and older, dosing is weight-based; see Pediatric Uses and Dosage.
• Elderly patients: older adults are at higher risk of gastrointestinal bleeding, cardiovascular events, and kidney problems with Cpfen; the lowest effective dose for the shortest duration should be used, with closer monitoring.
• Renal impairment: Cpfen should be used with caution in patients with reduced kidney function, as it can further reduce kidney blood flow; it should generally be avoided in patients with severe renal impairment, and kidney function should be monitored during use.
• Hepatic impairment: Cpfen should be used with caution in patients with liver disease; it should generally be avoided in severe hepatic impairment, and periodic monitoring of liver function is advisable with prolonged use.
• Cardiovascular disease: patients with a history of heart disease, high blood pressure, or stroke should use Cpfen only when needed and at the lowest effective dose, given the cardiovascular risks described in Precautions and Warnings.
• Pregnant and breastfeeding women: see Pregnancy and Lactation for detailed, trimester-specific guidance.

For self-care of fever or minor aches and pains, Cpfen should generally not be used for more than 3 days for fever or more than 10 days for pain without consulting a doctor; if symptoms persist or worsen, medical advice should be sought. For chronic conditions such as rheumatoid arthritis or osteoarthritis, Cpfen is used for longer periods only under the supervision of a healthcare professional, who will periodically reassess the need for continued treatment, the dose, and the risk of gastrointestinal, cardiovascular, and renal side effects. In all cases, the general principle is to use the lowest effective dose of Cpfen for the shortest duration that achieves the treatment goal.

Cpfen is guideline-supported, per current AAP-aligned pediatric dosing guidance, for the relief of fever and mild to moderate pain in infants and children 6 months of age and older. It is not recommended for infants younger than 6 months except under a doctor's specific direction, because safety in this age group has not been established for routine self-care use. For children 6 months to 12 years, the typical dose is 5-10 mg/kg of body weight by mouth every 6-8 hours as needed, not exceeding 40 mg/kg per day or 4 doses in 24 hours, whichever is lower; a doctor or pharmacist should confirm the exact dose based on the child's current weight and the specific product/concentration used. Children 12 years and older may use adult self-care dosing of Cpfen (see Dosage). As with adults, Cpfen should be given with food or milk to reduce stomach upset, and combination cough/cold products already containing Cpfen or another NSAID should not be added on top of a separate dose of Cpfen.